In an ongoing clinical trial, researchers are adding c-MET inhibitors (APL-101) for combination therapy in NSCLC patients receiving first-line osimertinib treatment between 8 and 12 weeks before the occurrence of resistance, to observe whether this treatment regimen can delay the onset of resistance in patients (NCT04743505). This evidence concerns the gene MET and non-small cell lung carcinoma.